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The EphA2 receptor tyrosine kinase is overexpressed in a variety of human epithelial cancers and is a determinant of malignant
cellular behavior in pancreatic adenocarcinoma cells. Moreover, it is expressed in tumor endothelium and its activation promotes
angiogenesis. To better clarify the therapeutic potential of monoclonal antibodies (mAbs) directed to the EphA2 receptor, we
generated a large number of mAbs by diﬀerential screening of phage-Ab libraries by oligonucleotide microarray technology
and implemented a strategy for the rapid identiﬁcation of antibodies with the desired properties. We selected two high-aﬃnity
and highly speciﬁc EphA2 monoclonal antibodies with diﬀerent in vitro properties on the human pancreatic tumor cell line
MiaPaCa2. One is a potent EphA2-agonistic antibody, IgG25, that promotes receptor endocytosis and subsequent degradation,
and the second is a ligand antagonist, IgG28, that blocks the binding to ephrin A1 and is cross-reactive with the mouse EphA2
receptor. We measured the eﬀect of antibody treatment on the growth of MiaPaCa2 cells orthotopically transplanted in nude mice.
Both IgG25 and IgG28 had strong antitumor and antimetastatic eﬃcacy. In vivo treatment with IgG25 determined the reduction
of the EphA2 protein levels in the tumor and the phosphorylation of FAK on Tyr576 while administration of IgG28 caused a
decrease in tumor vascularization as measured by immunohistochemical analysis of CD31 in tumor sections. These data show that
in a pancreatic cancer model comparable therapeutic eﬃcacy is obtained either by promoting receptor degradation or by blocking
receptor activation.
Copyright © 2009 Helenia Ansuini et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Ephreceptorsareauniquefamilyofreceptortyrosinekinases
(RTK) that play critical role in embryonic development and
in human diseases [1]. The ligands of Eph receptors, called
ephrins, are bound to the cell membrane and are involved in
cell to cell contact for ligand-receptor interaction.
Eph-ephrin complexes can generate bidirectional signals
that aﬀect both the receptor-expressing and ligand-exp-
ressing cells [2, 3]. Eph receptor “forward” signaling depends
on the tyrosine kinase domain, which mediates autophos-
phorylation and phosphorylation of other proteins, and on
the association with various eﬀector proteins. Ephrin ligands
trigger a “reverse” signaling by association with other pro-
teins. Eph receptor signaling has been implicated in cell-cell
repulsion and adhesion, tissue patterning, and angiogenesis
[4].
EphA2 is over-expressed in diﬀerent types of cancer
including pancreatic, lung, melanoma, colorectal, ovarian,
and breast [5, 6]. However, despite the strong correlation
of EphA2 receptor expression with malignant phenotypes,
the mechanism by which EphA2 contributes to tumor cell
malignancy is far from clear [4–6]. Some evidence suggests
that EphA2 receptor phosphorylation is not necessary to
confer kinase activity and tumorigenicity [7, 8]o ri se v e n
tumor suppressive [9]. Other data suggest that EphA2
receptor phosphorylation is important in conferring the
oncogenic potential [10–12]. Not only tumor cells but2 Journal of Oncology
also tumor endothelium expresses a high level of EphA2,
suggesting a role for the receptor within the tumor cell and
in the surrounding tumor microenvironment [10, 13].
Targeting of EphA2 with antisense oligonucleotides or
monoclonalantibodies(mAbs)inducingproteosomaldegra-
dation of membrane-bound receptor reverses breast and
pancreatic adenocarcinoma cell growth [14, 15]. Similarly,
recent studies showed the eﬀectiveness of soluble EphA2-
Fc receptor in inhibiting tumor angiogenesis in a xenograft
model of human pancreatic carcinoma [11]. Therefore
pancreatic tumor cells appear to be sensitive to EphA2
targeting by diﬀerent mechanisms.
The aim of the present work was to generate monoclonal
antibodies to evaluate the therapeutic potential of targeting
EphA2 in pancreatic tumor. We have developed an antibody
that mimics the natural ligand and activates receptor sig-
naling and another which competes with the ligand thereby
blocking both “forward” and “reverse” signaling. The data
obtained demonstrate that in pancreatic cancer anti-tumor
activity can be achieved targeting EphA2 with diﬀerent mec-
hanisms.
2.MaterialsandMethods
2.1. Cell Lines and Clones. Human pancreatic MiaPaCa2,
Neuro-2a (N2a), and Hek293 were obtained from American
Type Culture Collection and cultured according to spec-
iﬁcations. The mouse EphA2-expressing colon carcinoma
cell line MC38-CEA has been previously described [16].
To generate the stable Hek293 cell line expressing EphA2
in an inducible manner, 293/EphA2, the human EphA2
cDNA (NM 004431) was cloned from Origene Full Length
Clone into the inducible expression vector pCEPTetO-MCS.
The resulting vector carried hEphA2 cDNA downstream of
CMV promoter. The CMV promoter was preceded by the
TetO cassette, allowing EphA2 expression upon doxycycline
induction. Stably transfected 293 EBNATet cells clones were
selected by hygromycin [17] and EphA2 expression was
conﬁrmed by FACS analysis after 16 hours of doxycycline
induction. Human full length cDNA clones EphA1, EphA2,
and EphA5 (Origene), EphA3, and EphA7 (Invitrogen and
GeneCopoeia, resp.) were transferred into pcDNA-DEST40
Vector (Invitrogen) by recombination reaction. Human full
length EphA4 cDNA (Open Biosystems) was subcloned
into pENTR1A and transferred into pcDNA-DEST40 Vector
by recombination reaction. N2a cell line was transfected
using Lipofectamine 2000, according to the manufacturer
instructions.
2.2. Selection of Anti-EphA2 mAbs. Panning of the tagged
4k Mbr phage-Ab library was performed on induced and
not-induced 293/EphA2 as described [18]. 107 cells were
incubated with 1011 phage. Following extensive washing,
cell-bound phage was eluted and used to infect TG1 cells.
Ampicillin-resistant bacterial colonies were collected and
phagemid DNA puriﬁed. Tag sequences were ampliﬁed by
PCR, labeled with Cy5 or Cy3 dyes, and assembled in
Hybridization mix. Images were acquired by Agilent scanner
and processed using Feature Extraction software (v 9.1,
Agilent Technologies). Rescue of scFv associated to selected
tags and scFv conversion to IgG class 1 were performed as
described [18].
2.3. Apparent Kd Determination of Anti-EphA2 mAbs. Mia-
PaCa2 cells (3 × 105) were incubated with antibodies or
ephrinA1/Fc ligand (R&D Systems) in PBS 1% BSA, 10mM
HEPES (FACS buﬀer) then binding was revealed by APC-
conjugated anti-human Fc antibody (Jackson ImmunoRe-
search). FACS acquisition and analysis were performed
using FACSCanto (Becton Dickinson) and BD FACSDiva
software. Mean Fluorescence Intensity (MFI) values were
analyzed by Sigma-Plot software. For competition experi-
ments, MiaPaCa2 cells were incubated in FACS buﬀer with
increasing concentrations of the antibodies; then the ligand
ephrinA1/Fc labeled with Zenon Alexa Fluor 647 IgG label-
ing kit (Invitrogen) was added at saturating concentration
(30nM).
2.4. Western Blot Analysis of Cell and Tumor Lysates. App-
roximately 50–100mgs of frozen tumor were lysed in Mixer
Mill MM300 homogenizer (QIAGEN) for 2 minutes in
TPER buﬀer (Pierce) supplemented by 0.5uM okadaic
acid (Calbiochem), protease inhibitor cocktail (Roche), and
Halt phosphatase inhibitor cocktail (Pierce). After overnight
(ON) starvation, MiaPaCa2 cells were incubated 2 hours in
complete medium and 15 minutes with Ctrl IgG, IgG25, or
IgG28 (10μg/mL) and ephrinA1-Fc (5μg/mL). Cells were
lysed in TPER buﬀer, 10 minutes at 4◦C. 30μga n d5 0μgp e r
lane of cell and tumor lysate, respectively, were loaded, trans-
ferred onto nitrocellulose, and probed with the following
primary antibodies: anti-EphA2, (Santa Cruz Biotechnol-
ogy), anti-FAK (Upstate), anti-FAKpY576 (Biosource), anti-
Akt (Cell Signalling Technology cat. 9272), anti-phosphoAkt
(Cell Signalling Technology), and anti-phosphoERK (Santa
Cruz Biotechnology). Secondary antibodies were antirabbit
IgG- HRP diluted (Pierce) or antimouse HRP (Promega).
Images were acquired by luminescent image analyzer LAS
3000 and then quantiﬁed by MultiGauge ver 2.2 software
(FUJIﬁlmScience).Toverifyequivalentsampleloading,blots
w e r es t r i p p e da n dr e p r o b e df o rβ-actin (NeoMarkers).
2.5. EphA2 Immunoprecipitation. Cells were incubated with
Ctrl IgG, IgG25, or IgG28 (10μg/mL) and ephrinA1-Fc
(5μg/mL) for 20 minutes at 4◦Ca n df o r5m i n u t e sa t
37
◦C. Cell lysates were incubated ON at 4◦C with Protein
G Sepharose beads (GE Healthcate) coated with anti-EphA2
antibody (Santa Cruz; 0.8μg/sample). Washed beads were
resuspended in SDS loading dye. Recovered proteins were
analyzed by western blotting with anti-pTyr 4G10 antibody
(Upstate). After stripping the ﬁlters were probed with anti-
EphA2 antibodies.
2.6. EphA2 Internalization Assay. Cells were ﬁrst precooled
at 4◦Cf o r1 0m i n u t e si nH B S Sb u ﬀer and then incubated 30
minutes at 4◦C with IgG25, IgG28, and ephrinA1-Fc (at 1,
0.2 and 0.5ug/mL, resp.). Cells were then shifted at 37
◦Cf o rJournal of Oncology 3
0, 30, 60, and 90 minutes, ﬁxed in 2% paraformaldehyde for
15 minutes at RT, and labeled with an antihuman IgG Alexa
A647 conjugated (Invitrogen). Secondary antibody was
diluted in permeabilization buﬀer (0.1% Triton;1mg/mL
BSA in PBS). Hoechst was used as nuclear marker. Images
were acquired at In Cell Analyzer 1000 instrument. Four
ﬁelds for each well were acquired at 20× magniﬁcation and
the internalization was measured by counting the number
of positive vesicles per cell by using Multitarget Analysis
algorithm.
2.7. In Vivo Eﬃcacy Studies. Female athymic nude mice
(Harlan) 5 weeks old were maintained in accordance with
the guide for the care and use of laboratory animals (IRBM
was awarded with Full AAALAC Accreditation since January
2008). 70%–80% conﬂuent MiaPaCa2 cells were harvested,
washed, and resuspended in PBS at 2 × 107 cells/mL. Mice
wereanesthetizedunderisoﬂuoraneinhalation,pancreaswas
exposed by an abdominal ﬂank incision, and 50uL of cell
suspension were injected subcapsularly in a region of the
pancreas just beneath the spleen. Biweekly i.p. treatment
with 2mg/kg of IgG25, IgG28, or Ctrl IgG started 24 hours
postcell inoculation. Mice were euthanized at day 35 and
tumors were excised, weighed, and either frozen in liquid
nitrogen or ﬁxed for immunohistochemistry.
2.8. IgG Quantiﬁcation in Mouse Sera. Mouse sera collected
1 hour, 8 hours, 24 hours, 48 hours, 96 hours, 192 hours,
12 days, 16 days, and 22 days post single IgG administration
at 50μg, were put on ELISA plates coated with antihuman
IgG(Bethyl).PuriﬁedhumanIgGwasusedasstandard.Goat
antihuman IgG HRP conjugate (Bethyl) was added to reveal
the human antibodies. Absorbance at 450nm was measured
with Saﬁre (TECAN).
2.9. Immunohistochemistry. Tumors were ﬁxed in 10%
buﬀered formalin and embedded in paraﬃn. 5μmm i c r o -
tome sections were cleared in xylol and rehydrated, the
unmasking procedure was carried out in antigen retrieve
solution (DAKO S1699), 99
◦C for 40 minutes and then
washed and blocked with 1.5% goat serum and 1% Triton in
PBS for 20 minutes RT. Anti-CD31 antibody (Pharmingen)
was added ON at 4◦C and binding was revealed with an
antirat antibody (VECTOR labs) incubated for 30 minutes
RT. Signal was ampliﬁed with ABC kit (VECTOR labs).
Sections were counterstained with Herris’ haematoxylin and
then dehydrated and mounted with Entellan (Merck KGaA).
Three sections/samples at three diﬀerent levels in the tumor
were analyzed by AxioVision software (Zeiss). CD31 positive
area was measured in each whole section.
2.10. Statistical Analysis. Statistical analysis was performed
applying the Student’s t-test. Probability associated with a
Student’s homoscedastic t-test, with a two-tailed distribu-
tion, was considered signiﬁcant when < 0.05. For the analysis
of the anti-tumor eﬀect in vivo, we ﬁrst assessed whether
there was a group eﬀect using ANOVA and rejected the null
hypothesisofnodiﬀerencebetweengroupandoverallmeans
(P = .001). We then proceeded with an a priori contrast
analysis, assessing if treatments were diﬀerent from control
and diﬀerent from each other.
3. Results
3.1. Selection and Characterization of Anti-EphA2 mAbs.
We have recently developed a tagArray technology that
allows the rapid identiﬁcation of antibodies out of a library
(Membranome collection) of phage-displayed antibodies
which bind to receptors expressed on the membrane of
tumor cell lines [18]. Hek293 cells expressing EphA2 under
a doxycycline-inducible promoter (293/EphA2) and the
matched noninduced cell line were used as selectors to
pan the library. By this approach 30 speciﬁc clones were
selected and converted into fully human IgG class 1. This
strategy generated mainly mAbs which bound to EphA2
conformational epitopes because they did not recognize the
denatured form of the protein (data not shown).
MAb’sspeciﬁcitywasconﬁrmedbybindingnativeEphA2
displayed on 293/EphA2 only upon doxycycline induction
of receptor expression. The apparent Kd was determined by
FACS in a whole-cell binding assay on the human pancreatic
cell line MiaPaCa2 and only high-aﬃnity antibodies were
selected (Kd < single digit nM). Next, the selectivity of
the antibodies was determined after transfection of N2a
cells with commercially available cDNAs coding for EphA1,
EphA2, EphA3, EphA4, EphA5, and EphA7, followed by
whole cell binding assay and FACS analysis. Few antibodies
showed some degree of cross-reactivity to EphA4 and were
discarded (data not shown).
To identify agonistic mAbs, the level of EphA2 phos-
phorylation was measured after treatment of MiaPaCa2
cells followed by immunoprecipitation with anti-EphA2
antibodiesandWesternblotwithanti-pTyrosine.ThenmAbs
were assayed in competition with the ephrinA1-Fc ligand
in a whole-cell binding assay. This screening funnel led
to the identiﬁcation of two antibodies, IgG25 and IgG28,
w h o s ec h a r a c t e r i s t i c sa r es u m m a r i z e di nFigure 1:b o t h
antibodies bound to the receptor with high-aﬃnity, IgG25
Kd = 1.3nM and IgG28 Kd = 1.5nM (Figure 1(a)). When
tested on the mouse EphA2-expressing colon cancer cell line
MC38-CEA, only IgG28 showed high aﬃnity cross-reactivity
to the murine EphA2 receptor Kd = 1nM (Figure 1(b))
and was competitive with the ephrinA1-Fc ligand with
an IC50 = 0.89nM (Figure 1(c)). IgG25 triggered receptor
phosphorylation in a comparable manner with respect to
the ligand, while IgG28 did not induce receptor phosphory-
lation (Figure 1(d)). Finally, as previously mentioned, both
antibodies selectively bound to EphA2 and did not recognize
other receptors of the A family (Figure 1(e)).
The property of IgG25 and IgG28 to induce receptor
internalization and degradation was studied by epiﬂuores-
cence microscopy and imaging using InCell 1000 and by
Westernblotanalysisoftotalcelllysatesafterincubationwith
MiaPaCa2 cells at various times. Similarly to the ephrinA1
ligand, IgG25 rapidly induced receptor internalization lead-
ing to a punctuate staining typical of internalization through
the endosomal pathway (Figure 2(a)) and more than 70%4 Journal of Oncology
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Figure 1: In vitro characterization of IgG25 and IgG28. (a) FACS-based whole cell binding assay was performed with IgG25 and IgG28 on
human MiaPaCa2 and (b) on mouse MC38-CEA cells to determine the apparent Kd. Mean Fluorescence Intensities (MFIs) obtained with
IgG25 and IgG28 over the logarithm of their molar concentration (LogM) are reported. (c) Binding competition experiments of IgG25 and
IgG28 with ephrinA1 on MiaPaCa2 cells, a control isotypic IgG1 antibody (Ctrl IgG) was used as negative control. IgG25 (ﬁlled circles),
IgG28 (empty circles), Ctrl IgG (ﬁlled triangles). (d) EphA2 immunoprecipitation from lysates of cells treated with Ctrl IgG, IgG25, IgG28
andephA1-Fc,followedbyWesternBlotwithantiphosphotyrosineantibody.Afterstripping,thesameﬁlterwasprobedwithEphA2antibody
as loading control. (e) FACS-based whole cell binding with IgG25 and IgG28 on mouse N2A cells transiently transfected with expression
vectors coding for members of Eph A receptor family (EphA1, EphA2, EphA3, EphA4, EphA5, and EphA7).Journal of Oncology 5
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Figure 2: IgG25- and IgG28-mediated EphA2 internalization and degradation in MiaPaCa2 cells. (a) EphA2 internalization in response
to IgG25, IgG28, and ephrinA1-Fc treatment. mAbs and ephrinA1-Fc labeled in red while cell nuclei in blue. Images were acquired at
20× magniﬁcation. Localization was revealed 1 hour after incubation on cells either at 4◦Co ra t3 7
◦C. (b) Time course Western blot
analysis of EphA2 degradation after treatment with control IgG, IgG25, IgG28, and ephrinA1-Fc; anti-β-actin was used as loading control.
(c) Densitometric analysis of the level of EphA2 expression measured by Western Blot in cells treated with control IgG (asterisks), IgG25
(squares), IgG28 (triangles), and ephrinA1-Fc (circles). Data are expressed as percentage of EphA2 expression over time.
of EphA2 was degraded after 4 hours, as shown by Western
blot analysis (Figures 2(b) and 2(c)). IgG28 showed a typical
membranestaining(Figure 2(a))anddidnottriggerreceptor
degradation (Figures 2(b) and 2(c)).
3.2.InVitromAb-DependentPathwayActivationinPancreatic
Tumor Cells. To investigate EphA2 downstream signaling in
MiaPaCa2 cells after incubation with ephrinA1-Fc, IgG25,
and IgG28 and with an isotypic IgG control for 15 minutes,
t o t a le x t r a c t sw e r ea n a l y z e db yW e s t e r nb l o to fp E R Ka n d
pAkt. As expected, due to the mutant K-RAS harbored
by this cell line, both Erk1 and Erk2 were constitutively
phosphorylated and signal intensities did not change after
treatment with ligand or any of the mAbs (Figure 3).
Interestingly,wefoundamoderatebutreproducibledecrease
in the level of Akt phosphorylation after treatment with both
IgG25 and the ligand ephrinA1 while IgG28 treatment did
not alter Akt phosphorylation (Figure 3). These data suggest
that EphA2 receptor activation in MiaPaCa2 cells leads to
downregulation of the PI3Kinase pathway. IgG25 and IgG28
had no eﬀect on MiaPaCa2 cell proliferation as measured by
viability assay (ViaLight) or BrdU incorporation (data not6 Journal of Oncology
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Figure 3: EphA2 downstream signaling in MiaPaCa2 cells treated
with IgG25 and IgG28. Cell lysates of MiaPaCa2 were assayed by
Western Blotting with antiphospho-Akt, antiphospho-ERK, and
anti-phospho FAK (Tyr 576). Antibodies directed to total Akt, total
FAK, and actin were used as loading controls.
shown), though we have shown that in vitro IgG25 and the
ligand induced biochemical changes which are known to be
proapoptotic.
It has been reported that EphA2 receptor can interact
directly with FAK, an important mediator of growth factor
signaling, cell survival, and cell migration. Therefore FAK
signaling was studied in MiaPaCa2 cells incubated with
IgG25, IgG28, ephrinA1 ligand, and an isotypic IgG control
for 15 minutes at 37
◦C. No association of FAK with EphA2
was detected after immunoprecipitation with antibodies
against either of the two molecules (data not shown) and
no decrease in FAK phosphorylation was observed. Rather,
as shown in Figure 3, when the cells were incubated with
IgG25 and ephrinA1 FAK was phosphorylated on Tyr576,
IgG28 binding on MiaPaCa2 cells did not induce FAK
phosphorylation. These data indicate that EphA2 kinase
activation is needed to achieve phosphorylation of FAK on
Tyr 576.
The results of mAb dependent pathway activation
conﬁrm that the two EphA2 antibodies have functionally
opposite behavior in vitro, IgG25 is an agonist, mimicking
the natural ephrinA1 ligand, while IgG28 is an antagonist of
EphA2 forward signaling.
3.3. Antitumor and Antimetastatic Eﬃcacy of mAbs in
MiaPaCa2 Orthotopic Tumor Xenograft Model. The in vivo
anti-tumor property of each antibody and the eﬀect of
their combination have been studied in a mouse xenograft
model of human pancreatic cancer. Ten mice orthotopically
implanted with 1 million MiaPaCa2 cells into the pancreas
were treated biweekly with 2mg/kg of IgG25 and IgG28
alone or in combination. A control group was treated
with the same dose of an isotypic human IgG1. Dosing
schedule was established on the basis of preliminary mAb
pharmacokinetic analyses in mice. Terminal half life of
144 and 72 hours was measured for IgG25 and IgG28,
respectively (Figure 4(a)). This diﬀerence could be explained
by a “metabolic sink” due to IgG28 binding to the mouse
receptor. Repeating the dose every 72 hours, the trough level
of both antibodies remained above the concentration needed
for receptor saturation, as conﬁrmed by FACS analysis of
MiaPaCa2 cells incubated with serum withdrawn 72 hours
after mAb administration (data not shown). Thirty-ﬁve days
after implantation mice were euthanized, tumors weighted,
and metastases counted after necropsy. Data shown in Fig-
ures 4(b) and 4(c) demonstrate that both IgG25 and IgG28
induced a strong reduction (50% on average) in primary
tumor weight and in the number of metastases. These data
were statistically signiﬁcant either when applying a t-test
analysis (IgG25 P =.002; IgG28 P =.018), or when applying
a more complex analysis using ANOVA (see Material and
Methods) from which we concluded that treatment groups
were indeed diﬀerent from the control group (P =.0004) but
no diﬀerence was observed between the two IgG treatments
(P =.28).
Notably, administration of IgG28 which is cross-reactive
to the mouse EphA2 receptor did not cause weight loss or
clinical signs in any of the treated animals for the duration
of the study. Combination of IgG25 and IgG28 did not result
in additive inhibition of tumor growth or in the number of
metastases (data not shown).
In light of the role of EphA2 in angiogenesis [11, 19, 20],
the impact of IgG25 and IgG28 administration on tumor
vascularization was also monitored. Quantitative immuno-
histochemical (IHC) analyses of paraﬃne-embedded tumor
sections were performed to evaluate the level of vasculature
intumorsfromcontrolandtreatedmicebyCD31immunos-
taining (Figure 5(a)). The results showed a moderate but
statistically signiﬁcant decrease in the percentage of CD31
positive staining in tumors treated with IgG28 with respect
to untreated controls (P =.04) (Figure 5(b)).
These data show for the ﬁrst time that a selective
antagonist of EphA2 signal transduction has therapeutic
eﬃcacy in pancreatic cancer.
3.4. EphA2 Expression in Tumors. When explanted, 35 days
after continuous mAb administration, tumor masses were
still growth inhibited as revealed by the lower weight of
treated tumors versus controls. To gain information on
the mechanisms underlying the anti-tumor property of
the two antibodies, studies on EphA2 downregulation and
on activation of EphA2-related signaling molecules were
performed on tumor samples from control and treated
mice. Total level of EphA2 expression in tumor lysates was
evaluated by Western blot analysis.
As shown in Figure 6, IgG25 administration caused a
strong decrease of EphA2 receptor level (70% on average)
compared to untreated tumors (P =.0005), in line with what
previously reported on EphA2 agonistic antibodies. On theJournal of Oncology 7
0
5
10
15
20
25
I
g
G
/
s
e
r
u
m
(
μ
g
/
m
L
)
0 5 10 15 20 25
(day)
(a)
0
0.2
0.4
0.6
0.8
1
1.2
(
g
r
a
m
s
)
Ctrl IgG IgG25 IgG28
∗
∗
(b)
Metastatic incidence
Total metastasis
Ctrl IgG IgG25 IgG28
8/10 3/10∗ 3/10∗
48 9 16
(c)
Figure 4: In vivo activity of IgG25 and IgG28 in MiaPaCa2 orthotopic xenografts. (a) Pharmacokinetic analysis of IgG25 (empty circle)
and IgG28 (full circle) following a single dose at 2mg/kg. The straight line represents the trough level of the antibody before the next
administration. (b) Tumor weight at day 35 following biweekly administration of control IgG, IgG25, and IgG28. Data, expressed in grams,
representtheaverageoftumorweightfromtendiﬀerentanimals(N =10).Errorbarsindicatethestandarderror.(c)ImpactofIgGtreatment
on metastatization: the metastatic incidence is given by the number of mice with metastases in each group. The total number of metastases
counted for each group is also reported. Metastatic lesions were normally distributed in liver, spleen, stomach, diaphragm, and, in few cases,
kidney tissues. Involvement of local lymph nodes was not detected. Asterisks indicate statistically signiﬁcant diﬀerences with respect to the
control group (Student’s t-test; P< .05)
contrary, tumors treated with IgG28 showed a certain degree
of variability in EphA2 receptor levels but no statistically
signiﬁcant diﬀerence from the untreated controls (P =.22).
To rule out the possibility that the decreased level of
expression in IgG25-treated tumors might be due to altered
transcriptional level or to an EphA2 negative cell population
arising from the selective pressure of mAb treatment, EphA2
mRNA was quantiﬁed in tumor lysates by qPCR, but no
variation in the amount of transcript was detected between
the diﬀerent groups (data not shown).
3.5. Eﬀect of mAb’s Treatment on EphA2 Signaling In Vivo. To
determine the impact of antibody treatment on the pathways
downstream the EphA2 receptor in vivo, we determined the
levelofexpressionandphosphorylationofAkt,Erk,andFAK
in tumor lysates from control and treated mice. No change
was observed in the levels of both total and pErk (data not
shown), which was constitutively activated in vivo as it was
previously observed in vitro. Diﬀerently from what observed
in cultured cells, Akt was only poorly activated in untreated
tumors but the level of phosphorylation increased about 2-
fold on average in the case of tumors from mice treated
with IgG25 (P =.005) and more modestly 1.6-fold although
statistically signiﬁcant (P =.04) in tumors treated with IgG28
(Figure 7).Finally,bothIgG25andIgG28wereabletoinduce
an average of 3-fold increase in FAK phosphorylation on
Tyr576 (resp. P =.005 and P =.013) (Figure 7). Also this
latter observation diﬀers from what was observed in cultured
MiaPaCa2 cells where IgG28 treatment did not induce FAK
phosphorylation (Figure 3).
4. Discussion
TostudytheroleoftheEphA2receptorinapancreaticcancer
model two monoclonal antibodies with diﬀerent functional
properties have been selected and characterized.
One of the novel ﬁndings of the present study is the
identiﬁcation of a high-aﬃnity monoclonal antibody, IgG28,
selective for EphA2 and cross-reactive with the mouse
receptor which blocks the binding of the ephrinA1 ligand
to EphA2 expressed on human epithelial cells and on
mouse endothelia. When administered to mice orthotopi-
cally transplanted with pancreatic MiaPaCa2 tumor cells,
IgG28inhibitedtumorprogressionandmetastasisformation
and caused decreased tumor angiogenesis (Figures 4 and
5). Moreover, blocking the mouse EphA2 receptor with8 Journal of Oncology
(a)
0
3
6
9
C
D
3
1
+
a
r
e
a
(
%
)
Ctrl IgG IgG25 IgG28
∗
(b)
Figure 5:EﬀectofEphA2antibodiesonangiogenesis.(a)Represen-
tative CD31 immunostaining of paraﬃn embedded tumor section
(magniﬁcation bar = 20m). (b) Quantitative analysis of CD31
staining in tumors treated with control IgG, IgG25, and IgG28. The
average data obtained from the analyses of two tumors selected
from each group are reported as the percentage of CD31+ area
in each entire section. In all panels, asterisks indicate statistically
signiﬁcant diﬀerences with respect to the control group (Student’s
t-test; P< .05).
continuous treatment of IgG28 was not associated to overt
toxicityforthedurationofthestudy.Theobservedinhibitory
eﬀect on tumor vasculature was in agreement with previous
studies where a soluble EphA2/Fc receptor was used as a
receptor antagonist to block endogenous EphA2 signaling
[11, 19, 20]. Diﬀerently from the highly selective IgG28
antibody, the soluble EphA2 receptor can promiscuously
interact with diﬀerent ephrin ligands and block multiple
EphAreceptorsignalingpathwaysinthetumorendothelium.
Therefore, the precise target of such therapeutic approach
remains undeﬁned. By contrast, the use of a selective
antagonist allows focusing on the role of the EphA2 receptor
in tumor progression in vivo.
The eﬃcacy of the antagonistic antibody IgG28 was
compared with that of an agonistic antibody, IgG25, which
mimics the ephrinA1-Fc ligand in potency and kinetics
of EphA2 activation and degradation (Figure 2). The anti-
tumor eﬃcacy of the administration of either of the two
antibodies in xenograft models of MiaPaCa2 tumors was
comparable (Figure 4). Contradictory results have been
reported on the eﬀects of antibodies that decrease EphA2
expression in several epithelial tumors. A strong anti-tumor
activity has been reported using agonistic antibodies that
induce receptor phosphorylation followed by internalization
and degradation [14, 20]. In contrast, agonistic antibodies
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Figure 6: EphA2 protein expression in tumors from treated mice.
(a) Western Blot analysis with anti-EphA2 antibodies of lysates
fromﬁvetumorstreatedwithcontrolIgG,withIgG25,orsixtumors
treated with IgG28. (b) Densitometric analysis of the ratio between
EphA2 levels revealed by anti-EphA2 antibody in nonsaturating
conditions and actin expression measured with antiactin antibody.
Data on y axis are expressed as arbitrary units.
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Figure 7: IgG25 and IgG28 modulate in vivo EphA2 downstream
signaling: Western Blot analyses of tumor lysates with antiphospho
FAK (Tyr 576) and anti-phospho Akt. Antibodies to total Akt,
total FAK, and actin were used as loading controls. P values were
calculated with respect to average densitometric value of group
treated with control IgG.
have been shown not to inhibit the growth of breast and
colon tumor xenograft despite strong downmodulation of
EphA2 in tumors [21]. Here, we conﬁrm that IgG25 which
triggers receptor activation and downregulation was able to
inhibit the growth of a pancreatic xenograft model.
EphA2 agonistic antibodies are thought to function by
restoring a signal that is normally provided by receptor-
ligand binding but is lost in most cancer cells due to
poor receptor-ligand interactions [22]. To characterize the
response of cultured MiaPaCa2 cells to the antibody treat-
ment, a number of in vitro studies have been performed.
These cells harbor a mutated K-Ras and show constitutive
activation of pErk which does not change after exposure to
ephrinA1 or to the agonistic mAb, IgG25. A recent study has
demonstrated that EphA2 is a direct transcriptional target of
the Ras-Raf-MAPK pathway and that EphA2 signaling con-
tributes to a negative feedback loop regulating Ras activity in
a ligand dependent manner [23]. On the contrary, another
recent study in pancreatic cells lines showed that EphA2Journal of Oncology 9
activation weakly stimulates Erk phosphorylation in Mia-
PaCa2 cells [24]. The explanation for these diﬀerences is not
obvious, although it should be noted that diﬀerent condi-
tions of cellculture, serum starvation, and duration of ligand
incubation could contribute to the variability of the results.
Both ephrinA1 and IgG25 decrease pAkt levels
(Figure 3). This observation is in contrast with previous
data on MiaPaCa2 cells where Chang et al. found increased
Akt phosphorylation upon EphA2 activation [24]b u ti s
consistent with a recently published model in which the
EphA2 receptor mediates negative feedback inhibition of
PI3K-Akt in the presence of constitutive activation of the
Ras-Raf-MAPK pathway [25]. Furthermore, ephrinA1 and
IgG25 induce FAK phosphorylation on Tyr 576 (Figure 3),
conﬁrming what already observed in NIH3T3 cells and in
PC3 prostatic cancer cells [26, 27]. It is important to note,
however, that the often contrasting data reported on Erk,
Akt, and FAK signaling by EphA2 are context dependent and
no coherent picture has come up to date on the role of such
complex network in Eph-dependent tumor progression [1].
When we compared the data relative to EphA2 signal-
ing obtained from cultured MiaPaCa2 cells treated with
the antibodies with those obtained in MiaPaCa2 tumors
explanted from animals after prolonged antibody adminis-
tration we observed several discrepancies. Diﬀerently from
what observed in vitro, tumors treated with IgG28 showed
FAK Tyr 576 phosphorylation. Akt, which in cultured cells
showed a basal level of constitutive activity, was instead not
phosphorylated in untreated tumors but became activated
upon antibody treatment. One might speculate that the bio-
chemical signature observed after prolonged treatment with
the antibodies is the result of cellular adaptation. Therefore,
ongoing studies are focused on the investigation of the early
response of the tumor cells to the antibody treatment.
The data indicate that the most striking correlate to the
anti-tumor eﬃcacy of IgG25 is receptor downregulation.
This suggests that the mechanism by which reduction of
EphA2 expression is achieved is probably not relevant for
the growth inhibition of pancreatic tumors in mice. In fact
a signiﬁcant impact on tumor growth has also been reported
by siRNA-mediated knock down of EphA2 expression [15].
In contrast, the most likely correlate for the antitumor eﬀect
of IgG28 is the reduced angiogenesis in the tumor. The lack
of any additive therapeutic eﬀect in the coadministration
of the two antibodies may be due to the counteracting
activity on tumor receptor downregulation which results in
neutralization of growth inhibition.
While the present work demonstrates the usefulness of
monoclonal antibodies as tools for dissecting the therapeutic
potential of membrane receptor targets in tumorigenesis, it
also stresses the need for a thorough in vivo investigation of
antibody-based therapeutics to identify the real pharmaco-
dynamic marker that correlates with anti-tumor eﬃcacy.
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